January 28, 2022
Nippon Boehringer Ingelheim/Eli Lilly’s SGLT2 inhibitor Jardiance (empagliflozin) will be used to treat heart failure with reduced ejection fraction (HFrEF), which accounts for about half of chronic heart failure patients, a Japanese cardiologist said at a company-sponsored seminar on January...read more